Related Experiment Video
Updated: Feb 18, 2026
10:56
Assays for the Degradation of Misfolded Proteins in Cells
Published on: August 28, 2016
12.6K
SUMOylation and ubiquitination reciprocally regulate α-synuclein degradation and pathological aggregation
Ruth Rott1, Raymonde Szargel1, Vered Shani1
1Department of Biochemistry, Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa 31096, Israel.
Summary
SUMOylation, a process involving PIAS2, promotes α-synuclein aggregation in Parkinson's disease (PD) by hindering its degradation. Inhibiting SUMOylation may reduce α-synuclein levels and aggregation in PD.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- α-Synuclein accumulation is a key pathological feature of Parkinson's disease (PD).
- Ubiquitinated α-synuclein is typically degraded via proteasomal or lysosomal pathways.
- The role of SUMOylation in regulating α-synuclein levels and aggregation in PD is not fully understood.
Purpose of the Study:
- To investigate the role of SUMOylation in regulating α-synuclein degradation and aggregation in Parkinson's disease.
- To identify specific proteins involved in the SUMOylation of α-synuclein.
- To explore the therapeutic potential of targeting α-synuclein SUMOylation in PD.
Main Methods:
- Investigated the interaction between PIAS2, E3 ubiquitin ligases (SIAH, Nedd4), and α-synuclein.
- Utilized a SUMO E1 inhibitor (ginkgolic acid) to assess its effect on α-synuclein levels.
- Examined α-synuclein SUMOylation in disease mutants and post-mortem Parkinson's disease brain tissues.
- Analyzed the presence of SUMO1 and PIAS2 in Lewy bodies.
Main Results:
- PIAS2 promotes α-synuclein SUMOylation, decreasing its ubiquitination and leading to accumulation and aggregation.
- SUMOylation of α-synuclein by PIAS2 enhances its aggregation and blocks degradation pathways.
- Disease-associated α-synuclein mutants exhibit increased SUMOylation and aggregation.
- Increased PIAS2 and SUMOylated α-synuclein were detected in Parkinson's disease brains and Lewy bodies.
Conclusions:
- SUMOylation of α-synuclein by PIAS2 is a significant mechanism contributing to PD pathology.
- This SUMOylation process promotes α-synuclein aggregation through direct effects and by inhibiting degradation.
- Targeting α-synuclein SUMOylation presents a potential therapeutic strategy for reducing α-synuclein levels and aggregation in Parkinson's disease.
Related Concept Videos
01:13The Proteasome
1.8K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.8K
02:18The Proteasome
10.3K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.3K
02:58Regulated Protein Degradation
8.9K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.9K
02:58Regulated Protein Degradation
3.2K
3.2K
01:23Regulation of Expression at Multiple Steps
1.4K
The gene expression in cells is regulated at different stages: (i) transcription, (ii) RNA processing, (iii) RNA localization, and (iv) translation. Transcriptional regulation is mediated by regulatory proteins such as transcription factors, activators, or repressors—these control gene expression by initiating or inhibiting the transcription of genes. Once a precursor or pre-mRNA is produced, it undergoes post-transcriptional modification, including 5' capping, splicing, and the...
1.4K
02:04Covalently Linked Protein Regulators
9.7K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
9.7K